Health & Fitness
Mon, October 24, 2011Sat, October 22, 2011Fri, October 21, 2011Thu, October 20, 2011Wed, October 19, 2011Tue, October 18, 2011Mon, October 17, 2011Sun, October 16, 2011Sat, October 15, 2011Fri, October 14, 2011Thu, October 13, 2011Wed, October 12, 2011Tue, October 11, 2011Mon, October 10, 2011Sun, October 9, 2011Sat, October 8, 2011Fri, October 7, 2011Thu, October 6, 2011Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
Published in Health and Fitness on Friday, October 14th 2011 at 17:20 GMT by Market Wire
Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech... -- RICHMOND, Calif., Oct. 14, 2011 /PRNewswire/ --
Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
RICHMOND, Calif., Oct. 14, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: [ SGMO ]) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 9:30 am ET on Friday, October 21, 2011 at the 18th Annual Newsmakers in the Biotech Industry Conference which will be held in New York City.
The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section [ http://investor.sangamo.com/index.cfm ] under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.
About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. Sangamo has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins called zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence, Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at [ www.sangamo.com ].
ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.
SOURCE Sangamo BioSciences, Inc.
[ Back to top ] RELATED LINKS
[ http://www.sangamo.com ]
